Brussels, June 22, 2005 -- Janssen Pharmaceutica is performing as expected. In 2004, the company posted a turnover of 1,934 million euros and a net profit of 423 million euros. The employee headcount in Belgium decreased slightly over the past year by 43 units to a workforce of 4,343. Of particular note were the company's investments: 151 million euros in buildings, equipment and new technology and 938 million euros in Research & Development. Apart from several official visits, highlights in the past year included the announcement of promising molecules for the treatment of tuberculosis, leukemia and central nervous system disorders. The company also presented its second annual Sustainability Report on its operations in Belgium.

Strong Financial Results
Janssen Pharmaceutica realizes the major portion of its turnover within the Johnson & Johnson group. This turnover rose to 1.9 billion euros, of which 95% came from exports. Net profits grew to 423 million euros. The payroll rose by 14 million euros to 392 million euros.

The cash flow amounted to 887 million euros. The course of the cash flow over the past years indicates that the company is in good financial health.

Most Important Events in 2004
In 2004 a number of new buildings were inaugurated: the new Dr Paul Janssen Research Center (an investment of 67 million euros) and the Clinical Supplies Unit (16 million euros).

Investing in Research - a Promising Pipeline
Belgian investment in R&D reached a record 938 million euros, up by more than 30 million euros. Johnson & Johnson's pipeline includes promising new drugs, particularly for cancer, internal diseases and central nervous system disorders.

The most important announcement concerned a promising molecule for the treatment of tuberculosis, the first truly innovative treatment in 40 years. So important was this discovery that it featured in the cover article of the international scientific journal Science early in January 2005.

Sustainable Development
Janssen Pharmaceutica and Johnson & Johnson Pharmaceutical Research & Development also published their second annual Sustainability Report on activities carried out in Belgium. Based on 36 key performance indicators, the report provides an overview of the progress achieved with reference to business results, social affairs and the environment.

Johnson & Johnson's Results
In 2004, Johnson & Johnson realized a turnover of 47.3 billion dollars.
With a turnover of 22.1 billion dollars, the pharmaceutical group accounted for 46% of this sales volume and thus ranked as the fourth largest pharmaceutical company in the world.

Within the Johnson & Johnson group, Janssen Pharmaceutica is a worldwide Center of Excellence for integrated R&D, production and general services. In Belgium, the company has sites in Beerse, Geel and Olen. It has a total of 4,343 employees. In addition, 230 persons work at Janssen-Cilag in Berchem, which is responsible for the Belgian and Luxemburg markets. With over 80 drugs to its name, the company is one of the most innovative in the world and its products are used worldwide in human and veterinary medicine and for material protection. The company is involved in a wide variety of areas, such as gastroenterology, central nervous system disorders, oncology, pain control and infectious diseases.

Johnson & Johnson Pharmaceutical Research & Development is the worldwide pharmaceutical research division of Johnson & Johnson and is specialized in research into small molecules. The Belgian section of the research division employs 1,400 persons, or one third of J&J's research personnel worldwide. The research organization is world class and aims to become number one in the world in the discovery and development of innovative drugs.